Libby's H*O*P*E*

*Helping*Ovarian Cancer Survivors*Persevere Through*Education

Menu

Skip to content
  • Home
  • About
  • Mission
  • Warning Signs & Symptoms
  • Ovarian Cancer Overview
  • Prevention, Early Detection/Screening & Causes
  • Genetics
  • Types of Ovarian Cancer
  • Diagnosis & Staging
  • Treatment Overview
  • Surgery
  • Chemotherapy
  • Radiology & Radiation Therapy
  • Hormonal (Anti-Estrogen) Therapy
  • Biological (Immunotherapy & Vaccine) Therapy
  • Gene Therapy
  • Alternative & Complementary Therapy
  • Clinical Development
  • Clinical Trials
  • Coping
  • Survivorship
  • Ovarian Cancer Resources
  • Contact

Tag Archives: American Thoracic Society

Researchers Are On The TRAIL To Killing Cancer With Genetically-Engineered Adult Stem Cells

Posted on May 21, 2009 by Paul Cacciatore

“Researchers in London have demonstrated the ability of adult stem cells from bone marrow (mesenchymal stem cells, or MSCs) to deliver a cancer-killing protein to tumors.  The genetically engineered stem cells are able to home to the cancer cells, both in culture and in mouse models, and deliver TNF-related apoptosis-inducing ligand (TRAIL), destroying the tumor cells while sparing normal cells. …”

Continue reading →

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • Share on Pinterest (Opens in new window) Pinterest
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Reddit (Opens in new window) Reddit
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email
Like Loading...
Posted in Medical Study Results, Meeting Highlights, Novel Therapies | Tagged adult stem cells, American Thoracic Society, Centre For Respiratory Research, Medical Research Council UK, mesenchymal stem cells, Michael Loebinger M.D. M.A., ovarian cancer, S.M. Janes M.D. Ph.D., TNF-related apoptosis-inducing ligand, TRAIL, University College of London, vector | Leave a comment
"Once you choose hope, anything is possible." -- Christopher Reeve

Categories

RSS Google Ovarian Cancer News

  • Rezatapopt Shows 46% ORR in TP53 Y220C–Mutated Ovarian Cancer - Targeted Oncology
  • PMV Pharma’s Rezatapopt Achieves 44% Response Rate in TP53 Y220C Ovarian Cancer - The Clinical Trial Vanguard
  • 16th Biennial Rivkin Ovarian Cancer Research Symposium - Oncodaily
  • I thought retirement was my next chapter. Then came a stage 4 cancer diagnosis - Newsweek
  • Doctors recommend fallopian tube removal to prevent ovarian cancer - FOX Carolina News
  • ACOG Strengthens Ovarian Cancer Prevention Guidance - Medscape
  • ASCO Releases First Living Guideline for Recurrent Ovarian Cancer Care - Oncology Nursing News
  • Woman's Doctor: Katie's Corner helps women facing ovarian cancer - WBAL-TV
  • Raising awareness, spearheading research on ovarian cancer - 6abc Philadelphia
  • PMV cues up filing for first p53-directed cancer therapy - pharmaphorum

Top Posts

  • PI3K Pathway:  A Potential Ovarian Cancer Therapeutic Target?
    PI3K Pathway: A Potential Ovarian Cancer Therapeutic Target?
  • In-Depth Review: The Cancer Genome Atlas Reports On Landmark Analysis of High-Grade Serous Ovarian Cancer
    In-Depth Review: The Cancer Genome Atlas Reports On Landmark Analysis of High-Grade Serous Ovarian Cancer
  • The Mirror: "What is the Meaning of Life?"
    The Mirror: "What is the Meaning of Life?"
  • Mesothelin Antibodies Occur In Some Women With An Epidemiologic Risk For Ovarian Cancer.
    Mesothelin Antibodies Occur In Some Women With An Epidemiologic Risk For Ovarian Cancer.
  • Types of Ovarian Cancer
    Types of Ovarian Cancer
  • National Women's Health Week -- Learn, Spread the Word & Join!
    National Women's Health Week -- Learn, Spread the Word & Join!
  • Patty Franchi Flaherty Loses Battle to Ovarian Cancer, But Deserves a Long Standing Ovation
    Patty Franchi Flaherty Loses Battle to Ovarian Cancer, But Deserves a Long Standing Ovation
  • Improved Survival of Ovarian Cancer Patients Receiving Treatment Guided by Comprehensive Tumor Profiling
    Improved Survival of Ovarian Cancer Patients Receiving Treatment Guided by Comprehensive Tumor Profiling
  • Early Treatment of Recurrent Ovarian Cancer Based Upon Rising CA-125 Levels Does Not Increase Survival
    Early Treatment of Recurrent Ovarian Cancer Based Upon Rising CA-125 Levels Does Not Increase Survival
  • Elevated Proteins May Warn of Ovarian Cancer, But Sufficient Lead Time & Predictive Value Still Lacking
    Elevated Proteins May Warn of Ovarian Cancer, But Sufficient Lead Time & Predictive Value Still Lacking

Archives

  • May 2015
  • September 2014
  • August 2014
  • May 2014
  • March 2014
  • August 2013
  • May 2013
  • February 2013
  • January 2013
  • July 2012
  • June 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008

Blog Stats

  • 512,584 Visitors
cancer blog

Enter your email address to subscribe to Libby's H*O*P*E* & receive notifications of new posts by email.

Join 342 other subscribers

 Subscribe in a reader

Click on the orange button above if you want to (i) add Libby's H*O*P*E*(tm) updates to a web-based or other reader, or (ii) embed a Libby's H*O*P*E* (tm) update widget on your desktop, website or blog.

Donate To Ovarian Cancer Research

OCRF is the largest U.S. private funding agency supporting ovarian cancer research. It is a not-for-profit, 501(c)(3) organization. Click on the OCRF logo above to make a donation.

Strategic Partners

Podcasts

Join Us In the Fight Against Ovarian Cancer

RSS New Ovarian Cancer Clinical Trials (Past 14 Days)

  • Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1
  • A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
  • 89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer
  • Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
  • A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.
  • Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer
  • A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
  • Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer
  • Uterine Lavage to Detect Ovarian Cancer Risk
  • Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer

RSS New Adult Solid Tumor Clinical Trials (Past 14 Days)

  • HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors
  • Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer
  • A Study of RT023 in Patients With Advanced Solid Tumors
  • This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cancer.
  • Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1
  • Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors
  • Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)
  • A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
  • A Study of BL-M08D1 in Patients With Recurrent or Metastatic Gynecological Malignancies and Other Solid Tumors
  • Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer

RSS Medical Studies

  • A Meta-Analysis of the Impact of Lifestyle and Gynecologic Oncology Nursing Interventions on the Enhancement of Quality of Life
  • Non-parametric differential methylation analysis characterizes histotype-specific promoter regions in epithelial ovarian cancer
  • Natural compounds targeting glycolysis and TME in ovarian cancer: from metabolic crosstalk to therapeutic potential
  • Outcomes and Long-term Follow-up of Epithelial Ovarian Cancer: Experience from the Lead Cancer Center of Pakistan
  • Redox-neutral synthesis of azepane-fused spiroindolenines via Sc(OTf)3-catalyzed cascade [1,5]-hydride transfer/cyclization
  • Clinical Benefit of Pembrolizumab in Lynch Syndrome-Associated Advanced Ovarian Cancer With Germline MSH6 Variant: A Case Report
  • Antibody-drug conjugates and beyond in platinum-resistant ovarian cancer: A comprehensive review of emergent strategies
  • Evidence-based recommendations for advancing the chronic pelvic pain syndrome management by the paradigm change from reactive symptom suppression to proactive 3PM-guided patient-centered care
  • Altered ANG/TIE gene expression in advanced ovarian cancer is not accompanied by disproportionate body water accumulation relative to perioperative fluid balance
  • Small Extracellular Vesicle and Total Lipid Profiles Provide a Diagnostic Advantage Over CA-125 Across Ovarian Cancer Subtypes

Recent Comments

Prometey Bank's avatarPrometey Bank on World Ovarian Cancer Day: Toge…
mikaljhohnashly's avatarmikaljhohnashly on World Ovarian Cancer Day: Toge…
Jan C. Calthrop's avatarJan C. Calthrop on Lab-On-A-Chip: Veridex & M…
Paul Cacciatore's avatarPaul Cacciatore on About
Building a Team for… on About
Kathleen's avatarKathleen on About
Paul Cacciatore's avatarPaul Cacciatore on About
Liz's avatarLiz on About
Paul Cacciatore's avatarPaul Cacciatore on Dana Farber Webchat: The Lates…
Judith Marengere's avatarJudith Marengere on Dana Farber Webchat: The Lates…
Paul Cacciatore's avatarPaul Cacciatore on Dana Farber Webchat: The Lates…
Franca Pichini's avatarFranca Pichini on Dana Farber Webchat: The Lates…
painspeaks's avatarpainspeaks on SU2C Announces the Formation o…
marcy westerling's avatarmarcy westerling on SU2C Announces the Formation o…
anne's avataranne on Dana-Farber Oncologists Differ…

Blogroll

  • Site Meter Site Meter

Cancer Organizations

  • American Cancer Society
  • National Cancer Institute

Everyday Heroes

  • Are You There Cancer? It's Me, Jennie.
  • Bald Heads Are Sexy
  • Butterfly Ballet
  • Cancer Queen
  • Carrie's Journey
  • Chris Bledy
  • Diary of a Cancer Patient
  • I Want To Breathe
  • Janine's News
  • Journey Through Ovarian Cancer
  • Kristi & Brian: Living! With Cancer
  • Laurey Bikes
  • Life Cycle
  • livingly dying
  • Marcheline Bertrand Remembered
  • Meghan's Message
  • Monday Hearts For Madalene
  • My Journey With Teal
  • Nobody Has Ovarian Cancer
  • Out Shine Ovarian Cancer
  • OVACOM
  • Ovarian Cancer News
  • Ovarian Cancer?? pass the wine … now!
  • Scrambled Eggs, Surviving Ovarian Cancer
  • Shannon Miller Lifestyle
  • Still Smiling
  • Strong As Steele
  • Tenaciously Teal
  • The Carcinista
  • What? Me Worry?
  • Will There Be Cows In Heaven?
  • Women of Teal

Inspirational Cancer Advocates

  • Bald Is Beautiful
  • Bicycling For Ovarian Cancer (Craig Broeder)
  • Christine Druther
  • Fran Drescher
  • Imerman Angels
  • Jenn Sommermann: Training For a Cure
  • Jim Valvano
  • Laurey Masterton
  • Maddie Kullen
  • Mothers With Cancer
  • Randy Pausch
  • Sean Swarner
  • Standup2cancer
  • The Rock Band N.E.D.

Ovarian Cancer News Archive

  • Ovarian Cancer News Archive

Ovarian Cancer Organizations

  • National Breast & Ovarian Cancer Connection
  • National Ovarian Cancer Coalition
  • Ovarian Cancer National Alliance
  • Ovarian Cancer Research Fund
  • Ovations For the Cure

U.S. Treatment Centers

  • National Comprehensive Cancer Network Member Institutions
  • NCI-Designated Cancer Centers

Video Archive

  • Ovarian Cancer Video Library
Copyright 2008 - 2016 Paul Cacciatore, Libby's H*O*P*E*(TM), *Helping *Ovarian Cancer Survivors *Persevere Through *Education(TM), all rights reserved.
Paul Cacciatore

Create Your Badge
Site Meter
Blog at WordPress.com.
  • Subscribe Subscribed
    • Libby's H*O*P*E*
    • Join 217 other subscribers
    • Already have a WordPress.com account? Log in now.
    • Libby's H*O*P*E*
    • Subscribe Subscribed
    • Sign up
    • Log in
    • Report this content
    • View site in Reader
    • Manage subscriptions
    • Collapse this bar
%d